{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:23:37Z","timestamp":1789237417449,"version":"build-2803163510"},"reference-count":174,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472774"],"award-info":[{"award-number":["82472774"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3403200"],"award-info":[{"award-number":["2023YFC3403200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bbcan.2025.189333","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T19:02:44Z","timestamp":1745607764000},"page":"189333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["mRNA vaccines for prostate cancer: A novel promising immunotherapy"],"prefix":"10.1016","volume":"1880","author":[{"given":"Yaxiong","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyanling","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2025.189333_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2025.189333_bb0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0015","doi-asserted-by":"crossref","unstructured":"D. Tilki, R. van den Bergh, E. Briers, T. Van den Broeck, O. Brunckhorst, J. Darraugh, D. Eberli, G. De Meerleer, M. De Santis, A. Farolfi, G. Gandaglia, S. Gillessen, N. Grivas, A.M. Henry, M. Lardas, G. J L H van Leenders, M. Liew, E. Linares Espinos, J. Oldenburg, I.M. van Oort, D.E. Oprea-Lager, G. Ploussard, M.J. Roberts, O. Rouvi\u00e8re, I.G. Schoots, N. Schouten, E.J. Smith, J. Stranne, T. Wiegel, P.M. Willemse, P. Cornford, EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer, Eur. Urol., (2024).","DOI":"10.1016\/j.eururo.2024.04.010"},{"key":"10.1016\/j.bbcan.2025.189333_bb0020","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate Cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J. Urol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/ph17030351","article-title":"The current therapeutic landscape for metastatic prostate cancer","volume":"17","author":"Bernal","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bbcan.2025.189333_bb0030","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate Cancer: a review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.bbcan.2025.189333_bb0035","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41568-024-00699-2","article-title":"Exploiting temporal aspects of cancer immunotherapy","volume":"24","author":"Zemek","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189333_bb0040","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.immuni.2016.05.002","article-title":"Coinhibitory pathways in the B7-CD28 ligand-receptor family","volume":"44","author":"Schildberg","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2025.189333_bb0045","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0055","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(21)00693-8","article-title":"Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial","volume":"23","author":"Cella","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0060","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0065","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0070","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate Cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0075","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the Ipilimumab versus placebo following radiotherapy phase III trial in Postdocetaxel metastatic castration-resistant prostate Cancer identifies an excess of Long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0080","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus Ipilimumab for metastatic castration-resistant prostate Cancer: preliminary analysis of patients in the CheckMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189333_bb0085","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a BiTE(\u00ae) immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bbcan.2025.189333_bb0090","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.omto.2020.06.014","article-title":"PSMA-directed CAR T cells combined with Low-dose docetaxel treatment induce tumor regression in a prostate Cancer xenograft model","volume":"18","author":"Alzubi","year":"2020","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0095","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav0891","article-title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","volume":"11","author":"Puca","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-039639","article-title":"Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma","volume":"10","author":"Heitmann","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.bbcan.2025.189333_bb0105","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-20-3725","article-title":"The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor activity in preclinical models of metastatic castration-resistant prostate Cancer","volume":"27","author":"Deegen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189333_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.843604","article-title":"EpCAM as a novel biomarker for survivals in prostate Cancer patients","volume":"10","author":"Liao","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0115","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1380764","article-title":"Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer","volume":"7","author":"Priceman","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2025.189333_bb0120","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR Tcells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0125","first-page":"53","article-title":"Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine","volume":"9","author":"Huang","year":"2022","journal-title":"Mil. Med. Res."},{"issue":"2023","key":"10.1016\/j.bbcan.2025.189333_bb0130","article-title":"Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: a meta-analysis","volume":"4","author":"Zhang","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.bbcan.2025.189333_bb0135","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0140","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a Nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0145","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0150","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents","volume":"385","author":"Ali","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0155","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0160","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41591-021-01446-y","article-title":"Abu-Raddad, mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar","volume":"27","author":"Chemaitelly","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0165","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/s41591-021-01583-4","article-title":"BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar","volume":"27","author":"Tang","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0170","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S1473-3099(23)00295-5","article-title":"Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial","volume":"23","author":"Lee","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bbcan.2025.189333_bb0175","doi-asserted-by":"crossref","first-page":"835","DOI":"10.7150\/jca.80803","article-title":"Current status and progress of the development of prostate cancer vaccines","volume":"14","author":"Wang","year":"2023","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189333_bb0180","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3390\/vaccines12121384","article-title":"Vaccine therapies for prostate Cancer: current status and future outlook","volume":"12","author":"Zhou","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.bbcan.2025.189333_bb0185","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0190","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2101596","article-title":"Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines","volume":"11","author":"Hensler","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2025.189333_bb0195","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00262-017-2068-x","article-title":"Phase I\/II trial of dendritic cell-based active cellular immunotherapy with DCVAC\/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer","volume":"67","author":"Fucikova","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2025.189333_bb0200","doi-asserted-by":"crossref","first-page":"18192","DOI":"10.18632\/oncotarget.4145","article-title":"Phase I\/II clinical trial of dendritic-cell based immunotherapy (DCVAC\/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer","volume":"6","author":"Podrazil","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2025.189333_bb0205","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","article-title":"Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE phase 3 randomized clinical trial","volume":"8","author":"Vogelzang","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0210","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00126839-200607030-00006","volume":"7","year":"2006","journal-title":"Drugs R. D."},{"key":"10.1016\/j.bbcan.2025.189333_bb0215","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0220","author":"US National Library of Medicine"},{"key":"10.1016\/j.bbcan.2025.189333_bb0225","author":"US National Library of Medicine"},{"key":"10.1016\/j.bbcan.2025.189333_bb0230","author":"US National Library of Medicine"},{"key":"10.1016\/j.bbcan.2025.189333_bb0235","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002254","article-title":"Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer","volume":"9","author":"Sinha","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2025.189333_bb0240","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002903","article-title":"IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Pachynski","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2025.189333_bb0245","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1007\/s12325-022-02085-6","article-title":"Real-world effectiveness of Sipuleucel-T on overall survival in men with advanced prostate cancer treated with androgen receptor-targeting agents","volume":"39","author":"Hafron","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bbcan.2025.189333_bb0250","author":"US National Library of Medicine"},{"key":"10.1016\/j.bbcan.2025.189333_bb0255","author":"US National Library of Medicine"},{"key":"10.1016\/j.bbcan.2025.189333_bb0260","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1517\/14712598.7.12.1893","article-title":"GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer","volume":"7","author":"Ward","year":"2007","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.bbcan.2025.189333_bb0265","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41585-023-00739-w","article-title":"Vaccines as treatments for prostate cancer","volume":"20","author":"Rastogi","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0270","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1158\/1078-0432.CCR-06-0145","article-title":"Phase I\/II trial of an allogeneic cellular immunotherapy in hormone-na\u00efve prostate cancer","volume":"12","author":"Simons","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189333_bb0275","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1158\/1078-0432.CCR-06-2937","article-title":"Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189333_bb0280","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/cncr.23669","article-title":"Phase 1\/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer","volume":"113","author":"Higano","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2025.189333_bb0285","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/MOU.0b013e3280eb10eb","article-title":"Prostate cancer immunotherapy","volume":"17","author":"McNeel","year":"2007","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0290","author":"US National Library of Medicine"},{"key":"10.1016\/j.bbcan.2025.189333_bb0295","author":"US National Library of Medicine"},{"key":"10.1016\/j.bbcan.2025.189333_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.714822","article-title":"Cell fate reprogramming in the era of Cancer immunotherapy","volume":"12","author":"Zimmermannova","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0305","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0310","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate Cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0315","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1200\/JCO.2004.08.083","article-title":"Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the eastern cooperative oncology group","volume":"22","author":"Kaufman","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0320","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0090-4295(98)00539-1","article-title":"Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer","volume":"53","author":"Sanda","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.bbcan.2025.189333_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-4-1","article-title":"A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer","volume":"4","author":"DiPaola","year":"2006","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0330","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0335","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41391-021-00402-8","article-title":"Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer","volume":"25","author":"Drake","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.bbcan.2025.189333_bb0340","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/oncolo\/oyac048","article-title":"ADXS31142 immunotherapy \u00b1 Pembrolizumab treatment for metastatic castration-resistant prostate cancer: open-label phase I\/II KEYNOTE-046 study","volume":"27","author":"Stein","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2025.189333_bb0345","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189333_bb0350","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0355","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0360","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3892\/or.2020.7847","article-title":"A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel","volume":"45","author":"Noguchi","year":"2021","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2025.189333_bb0365","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/(SICI)1097-0045(20000501)43:2<88::AID-PROS3>3.0.CO;2-G","article-title":"Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer","volume":"43","author":"Meidenbauer","year":"2000","journal-title":"Prostate"},{"key":"10.1016\/j.bbcan.2025.189333_bb0370","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jnci\/89.4.293","article-title":"In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen","volume":"89","author":"Correale","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2025.189333_bb0375","doi-asserted-by":"crossref","first-page":"6933","DOI":"10.1158\/1078-0432.CCR-05-0682","article-title":"Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles","volume":"11","author":"Matsueda","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189333_bb0380","first-page":"41","article-title":"Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen","volume":"8","author":"Terasawa","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189333_bb0385","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/(SICI)1097-0045(199601)28:1<65::AID-PROS9>3.0.CO;2-N","article-title":"Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity","volume":"28","author":"Tjoa","year":"1996","journal-title":"Prostate"},{"key":"10.1016\/j.bbcan.2025.189333_bb0390","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/CJI.0b013e3181a80e0d","volume":"32","author":"Kouiavskaia","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.bbcan.2025.189333_bb0395","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1023\/A:1021904432489","article-title":"Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant","volume":"23","author":"McNeel","year":"2003","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0400","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.4161\/hv.20988","article-title":"Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer","volume":"8","author":"Sasada","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.bbcan.2025.189333_bb0405","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00262-015-1781-6","article-title":"A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer","volume":"65","author":"Noguchi","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2025.189333_bb0410","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00262-010-0822-4","article-title":"A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer","volume":"59","author":"Noguchi","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2025.189333_bb0415","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/14737140.2018.1531707","article-title":"Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies","volume":"18","author":"Matsui","year":"2018","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.bbcan.2025.189333_bb0420","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/sj.bjc.6602019","article-title":"A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer","volume":"91","author":"Pavlenko","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189333_bb0425","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.cji.0000165353.19171.41","article-title":"Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer","volume":"28","author":"Miller","year":"2005","journal-title":"J. Immunother."},{"key":"10.1016\/j.bbcan.2025.189333_bb0430","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.19.01701","article-title":"Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP [MVI-816]) in patients with progressive, nonmetastatic, castration-sensitive prostate cancer","volume":"37","author":"McNeel","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0435","doi-asserted-by":"crossref","first-page":"25586","DOI":"10.18632\/oncotarget.25387","article-title":"Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer","volume":"9","author":"McNeel","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2025.189333_bb0440","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008067","article-title":"Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer","volume":"11","author":"McNeel","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2025.189333_bb0445","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00262-012-1270-0","article-title":"DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time","volume":"61","author":"Chudley","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2025.189333_bb0450","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.ymthe.2020.02.018","article-title":"CD8(+) T cells impact rising PSA in biochemically relapsed Cancer patients using immunotherapy targeting tumor-associated antigens","volume":"28","author":"Shore","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2025.189333_bb0455","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/vaccines12010071","article-title":"Their formulations, engineering and delivery","volume":"12","author":"Kozak","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.bbcan.2025.189333_bb0460","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2022.10.013","article-title":"Challenges in neoantigen-directed therapeutics","volume":"41","author":"Lybaert","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189333_bb0465","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","article-title":"Neoantigen vaccine: an emerging tumor immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189333_bb0470","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.4161\/hv.29553","article-title":"mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer","volume":"10","author":"Rausch","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.bbcan.2025.189333_bb0475","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev-biophys-070816-034125","article-title":"Advances and assessment of 3D Structure prediction","volume":"46","author":"Miao","year":"2017","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.bbcan.2025.189333_bb0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13273-021-00171-4","article-title":"Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency","volume":"18","author":"Kim","year":"2022","journal-title":"Mol. Cell. Toxicol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104643","article-title":"Key considerations for a prostate cancer mRNA vaccine","volume":"208","author":"Lin","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.108015","article-title":"mRNA vaccine sequence and structure design and optimization: advances and challenges","volume":"301","author":"Jin","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2025.189333_bb0495","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2025.189333_bb0500","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2005.08.003","article-title":"TLR ignores methylated RNA","volume":"23","author":"Ishii","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2025.189333_bb0505","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.omtn.2023.05.004","article-title":"The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system","volume":"32","author":"Bernard","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bbcan.2025.189333_bb0510","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-1-0716-3770-8_7","article-title":"Production and evaluation of nucleoside-modified mRNA vaccines for infectious diseases","volume":"2786","author":"Vadovics","year":"2024","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0515","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1261\/rna.079942.124","article-title":"The molecular language of RNA 5\u2032 ends: guardians of RNA identity and immunity","volume":"30","author":"Avila-Bonilla","year":"2024","journal-title":"RNA"},{"key":"10.1016\/j.bbcan.2025.189333_bb0520","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1093\/nar\/gkw551","article-title":"mRNA capping: biological functions and applications","volume":"44","author":"Ramanathan","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2025.189333_bb0525","doi-asserted-by":"crossref","first-page":"9051","DOI":"10.1093\/nar\/gkac722","article-title":"2\u2019-O-methylation of the second transcribed nucleotide within the mRNA 5\u2032 cap impacts the protein production level in a cell-specific manner and contributes to RNA immune evasion","volume":"50","author":"Drazkowska","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2025.189333_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102045","article-title":"Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice","volume":"34","author":"Wang","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bbcan.2025.189333_bb0535","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","article-title":"Self-assembled mRNA vaccines","volume":"170","author":"Kim","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbcan.2025.189333_bb0540","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1261\/rna.7380904","article-title":"Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency","volume":"10","author":"Grudzien","year":"2004","journal-title":"RNA"},{"key":"10.1016\/j.bbcan.2025.189333_bb0545","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1261\/rna.5430403","article-title":"Novel \"anti-reverse\" cap analogs with superior translational properties","volume":"9","author":"Jemielity","year":"2003","journal-title":"RNA"},{"key":"10.1016\/j.bbcan.2025.189333_bb0550","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3390\/ph17050632","article-title":"The synergistic effect of N2 and N7 modifications on the inhibitory efficacy of mRNA cap analogues","volume":"17","author":"Kurpiejewski","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bbcan.2025.189333_bb0555","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/gt.2010.52","article-title":"Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo","volume":"17","author":"Kuhn","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.bbcan.2025.189333_bb0560","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189333_bb0565","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189333_bb0570","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","article-title":"Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2019 UTRs identified by cellular library screening","volume":"27","author":"Orlandini von Niessen","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2025.189333_bb0575","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring mRNA vaccine to balance innate\/adaptive immune response","volume":"26","author":"Linares-Fern\u00e1ndez","year":"2020","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0580","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2021.684088","article-title":"Radical prostatectomy: sequelae in the course of time","volume":"8","author":"Kesch","year":"2021","journal-title":"Front. Surg."},{"key":"10.1016\/j.bbcan.2025.189333_bb0585","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1186\/s12967-023-04553-1","article-title":"Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy","volume":"21","author":"Zhao","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0590","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA Vaccines for infectious diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0595","article-title":"Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy","volume":"14","author":"Imani","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0600","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3390\/vaccines11101620","article-title":"In silico analyses, experimental verification and application in DNA Vaccines of ebolavirus GP-derived pan-MHC-II-restricted epitopes","volume":"11","author":"Zhang","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.bbcan.2025.189333_bb0605","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/nsmb.3499","article-title":"Short poly(a) tails are a conserved feature of highly expressed genes","volume":"24","author":"Lima","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0610","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.3390\/ijms21186582","article-title":"mRNA vaccine era-mechanisms, drug platform and clinical prospection","volume":"21","author":"Xu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189333_bb0615","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.gde.2011.03.002","article-title":"Coordinate regulation of mRNA decay networks by GU-rich elements and CELF1","volume":"21","author":"Vlasova-St Louis","year":"2011","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.bbcan.2025.189333_bb0620","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1384","article-title":"mRNA vaccine in cancer therapy: current advance and future outlook","volume":"13","author":"Li","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0625","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.bbcan.2025.189333_bb0630","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1336906","article-title":"The mRNA-LNP vaccines - the good, the bad and the ugly","volume":"15","author":"Igy\u00e1rt\u00f3","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0635","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41541-023-00795-8","article-title":"Development and use of machine learning algorithms in vaccine target selection","volume":"9","author":"Bravi","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.bbcan.2025.189333_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.136643","article-title":"Vaccine development using artificial intelligence and machine learning: a review","volume":"282","author":"Asediya","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0645","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189333_bb0650","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189333_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.100996","article-title":"Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost\/Bayesian method and ensemble model approaches","volume":"14","author":"Maharjan","year":"2024","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.bbcan.2025.189333_bb0660","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1248\/cpb.c24-00089","article-title":"Understanding the manufacturing process of lipid nanoparticles for mRNA delivery using machine learning","volume":"72","author":"Sato","year":"2024","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.bbcan.2025.189333_bb0665","article-title":"Machine learning-driven advancements in liposomal formulations for targeted drug delivery: a narrative literature review","author":"Hoseini","year":"2024","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.bbcan.2025.189333_bb0670","doi-asserted-by":"crossref","first-page":"i381","DOI":"10.1093\/bioinformatics\/btae262","article-title":"Unveil cis-acting combinatorial mRNA motifs by interpreting deep neural network","volume":"40","author":"Zeng","year":"2024","journal-title":"Bioinformatics"},{"key":"10.1016\/j.bbcan.2025.189333_bb0675","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0022-2836(61)80072-7","article-title":"Genetic regulatory mechanisms in the synthesis of proteins","volume":"3","author":"Jacob","year":"1961","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0680","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1093\/nar\/12.18.7057","article-title":"Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs","volume":"12","author":"Krieg","year":"1984","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2025.189333_bb0685","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2025.189333_bb0690","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189333_bb0695","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0700","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0710","doi-asserted-by":"crossref","first-page":"12057","DOI":"10.1039\/c1cc14316f","article-title":"Efficient RNA synthesis by in vitro transcription of a triazole-modified DNA template","volume":"47","author":"el-Sagheer","year":"2011","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.bbcan.2025.189333_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26971","article-title":"The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases","volume":"10","author":"Deyhimfar","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bbcan.2025.189333_bb0720","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0725","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2025.189333_bb0730","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189333_bb0735","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-015-0068-y","article-title":"Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I\/IIa study","volume":"3","author":"K\u00fcbler","year":"2015","journal-title":"J. Immunother. Cancer"},{"issue":"Suppl. 3","key":"10.1016\/j.bbcan.2025.189333_bb0740","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/2051-1426-2-S3-P85","article-title":"A randomized, double-blind, placebo-controlled, phase I\/II trial of RNActive\u00ae-vaccine CV9104 in patients with metastatic castrate-refractory prostate cancer (mCRPC): first results of the phase I part","volume":"2","author":"Koch","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2025.189333_bb0745","doi-asserted-by":"crossref","first-page":"suppl_5","DOI":"10.1093\/annonc\/mdx376.014","article-title":"Results of the randomized, placebo-controlled phase I\/IIB trial of CV9104, an mRNA-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"28","author":"Stenzl","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0750","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004198","article-title":"Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)","volume":"10","author":"McNeel","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2025.189333_bb0755","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0760","first-page":"133","article-title":"Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer, Cancer","volume":"2","author":"Gulley","year":"2014","journal-title":"Immunol. Res."},{"key":"10.1016\/j.bbcan.2025.189333_bb0765","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12943-021-01452-1","article-title":"Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine","volume":"20","author":"Zheng","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189333_bb0770","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/pros.24027","article-title":"Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer","volume":"80","author":"Abudurexiti","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.bbcan.2025.189333_bb0775","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.7150\/jca.49567","article-title":"Increased expression of CELSR3 indicates a poor prognostic factor for prostate Cancer","volume":"12","author":"Chen","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189333_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109674","article-title":"Total saponins from Paris forrestii (Takht) H. Li. show the anticancer and RNA expression regulating effects on prostate cancer cells","volume":"121","author":"Xia","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2025.189333_bb0785","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1111\/cas.15546","article-title":"Identification and validation of a poor clinical outcome subtype of primary prostate cancer with Midkine abundance","volume":"113","author":"Zhou","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2025.189333_bb0790","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41568-020-0267-9","article-title":"Prostate carcinogenesis: inflammatory storms","volume":"20","author":"de Bono","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189333_bb0795","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1160972","article-title":"Subtype and prognostic analysis of immunogenic cell death-related gene signature in prostate cancer","volume":"13","author":"Kang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0800","first-page":"803","article-title":"Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression","volume":"2","author":"Lopez-Bujanda","year":"2021","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2025.189333_bb0805","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41419-022-05086-z","article-title":"Targeting HIC1\/TGF-\u03b2 axis-shaped prostate cancer microenvironment restrains its progression","volume":"13","author":"Wu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2025.189333_bb0810","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/cells11010020","article-title":"Myeloid-derived suppressor cells in prostate Cancer: present knowledge and future perspectives","volume":"11","author":"Koinis","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2025.189333_bb0815","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/pros.23885","article-title":"The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors","volume":"79","author":"Hellsten","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.bbcan.2025.189333_bb0820","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1002\/eji.201343472","article-title":"Polyunsaturated fatty acids promote the expansion of myeloid-derived suppressor cells by activating the JAK\/STAT3 pathway","volume":"43","author":"Yan","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0825","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fimmu.2014.00069","article-title":"The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment","volume":"5","author":"De Sanctis","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0830","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1084\/jem.20101956","article-title":"Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells","volume":"208","author":"Molon","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2025.189333_bb0835","first-page":"946","article-title":"PD-1 or PD-L1 blockade restores antitumor efficacy following SSX2 epitope-modified DNA vaccine immunization, Cancer","volume":"3","author":"Rekoske","year":"2015","journal-title":"Immunol. Res."},{"key":"10.1016\/j.bbcan.2025.189333_bb0840","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(12)70006-2","article-title":"Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial","volume":"13","author":"Madan","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0845","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.2020.38.6_suppl.126","article-title":"KEYNOTE-046 (part B): effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel","volume":"38","author":"Stein","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189333_bb0850","author":"US National Library of Medicine"},{"key":"10.1016\/j.bbcan.2025.189333_bb0855","author":"US National Library of Medicine"},{"key":"10.1016\/j.bbcan.2025.189333_bb0860","author":"US National Library of Medicine"},{"key":"10.1016\/j.bbcan.2025.189333_bb0865","author":"US National Library of Medicine"},{"key":"10.1016\/j.bbcan.2025.189333_bb0870","author":"US National Library of Medicine"},{"key":"10.1016\/j.bbcan.2025.189333_bb0875","author":"US National Library of Medicine"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25000757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25000757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:19:04Z","timestamp":1778213944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25000757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":174,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0304419X25000757"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189333","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA vaccines for prostate cancer: A novel promising immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189333"}}